Skip to main content
Erschienen in: Pneumo News 6/2020

20.10.2020 | Koronare Herzerkrankung | CME Fortbildung

Zusammenhänge zwischen Lungenerkrankungen und kardialer Dysfunktion

Was der Pneumologe aktuell über das Herz wissen muss

verfasst von: Dr. med. Benjamin Waschki

Erschienen in: Pneumo News | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Auszug

Es gibt vielfache Schnittstellen zwischen Pneumologie und Kardiologie, da Physiologie und Pathophysiologie von Lunge und Herz eng miteinander verzahnt sind. Am Beispiel des Kardinalsymptoms Luftnot und den zugrundeliegenden Differenzialdiagnosen wird die Verzahnung besonders deutlich.
Literatur
1.
Zurück zum Zitat Ponikowski P et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975 Ponikowski P et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975
2.
Zurück zum Zitat Westermann D et al. High-sensitivity assays for troponin in patients with cardiac disease. Nat Rev Cardiol. 2017;14(8):472-83 Westermann D et al. High-sensitivity assays for troponin in patients with cardiac disease. Nat Rev Cardiol. 2017;14(8):472-83
3.
Zurück zum Zitat Waschki B et al. High-sensitivity troponin I and all-cause mortality in patients with stable COPD: an analysis of the COSYCONET study. Eur Respir J. 2020; https://doi.org/10.1183/13993003.01314-2019 Waschki B et al. High-sensitivity troponin I and all-cause mortality in patients with stable COPD: an analysis of the COSYCONET study. Eur Respir J. 2020; https://​doi.​org/​10.​1183/​13993003.​01314-2019
4.
Zurück zum Zitat Knuuti J et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2019;41(3):407-77 Knuuti J et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2019;41(3):407-77
5.
Zurück zum Zitat Singh D et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. Eur Respir J. 2019;5 https://doi.org/10.1183/13993003.00164-2019 Singh D et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. Eur Respir J. 2019;5 https://​doi.​org/​10.​1183/​13993003.​00164-2019
6.
Zurück zum Zitat Maron DJ et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020;382(15):1395-407 Maron DJ et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020;382(15):1395-407
7.
Zurück zum Zitat Ibanez B et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2017;39(2):119-77 Ibanez B et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2017;39(2):119-77
8.
Zurück zum Zitat Valgimigli M et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2017;39(3):213-60 Valgimigli M et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2017;39(3):213-60
9.
Zurück zum Zitat Neumann FJ et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2018;40(2):87-165 Neumann FJ et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2018;40(2):87-165
10.
Zurück zum Zitat Mach F et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2019;41(1):111-88 Mach F et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2019;41(1):111-88
11.
Zurück zum Zitat Konstantinides SV et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Heart J. 2019;41(4):543-603 Konstantinides SV et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Heart J. 2019;41(4):543-603
12.
Zurück zum Zitat Baumgartner H et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38(36):2739-91 Baumgartner H et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38(36):2739-91
13.
Zurück zum Zitat Seiffert M et al. The DEDICATE Trial: An independent all-comers trial of transcatheter aortic valve implantation vs. surgical aortic valve replacement in patients at low to intermediate operative risk is recruiting patients. Eur Heart J. 2019;40(4):331-3 Seiffert M et al. The DEDICATE Trial: An independent all-comers trial of transcatheter aortic valve implantation vs. surgical aortic valve replacement in patients at low to intermediate operative risk is recruiting patients. Eur Heart J. 2019;40(4):331-3
14.
Zurück zum Zitat Kalbacher D et al. 1000 MitraClip™ procedures. Eur Heart J. 2019;40(38):3137-9 Kalbacher D et al. 1000 MitraClip™ procedures. Eur Heart J. 2019;40(38):3137-9
15.
Zurück zum Zitat Kalbacher D et al. Long-term outcome, survival and predictors of mortality after MitraClip therapy: Results from the German Transcatheter Mitral Valve Interventions (TRAMI) registry. Int J Cardiol. 2019;277:35-41 Kalbacher D et al. Long-term outcome, survival and predictors of mortality after MitraClip therapy: Results from the German Transcatheter Mitral Valve Interventions (TRAMI) registry. Int J Cardiol. 2019;277:35-41
16.
Zurück zum Zitat Hahn RT et al. Imaging Assessment of Tricuspid Regurgitation Severity. JACC Cardiovasc imaging. 2019;12(3):469-90 Hahn RT et al. Imaging Assessment of Tricuspid Regurgitation Severity. JACC Cardiovasc imaging. 2019;12(3):469-90
17.
Zurück zum Zitat Kirchhof P et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-962 Kirchhof P et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-962
18.
Zurück zum Zitat Brugada J et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC): Developed in collaboration with the Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2019;41(5):655-720 Brugada J et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC): Developed in collaboration with the Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2019;41(5):655-720
19.
Zurück zum Zitat Priori SG et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793-867 Priori SG et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793-867
20.
Zurück zum Zitat Chen W et al. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631-9. Chen W et al. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631-9.
21.
Zurück zum Zitat Rutten FH et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J. 2005;26(18):1887-94 Rutten FH et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J. 2005;26(18):1887-94
22.
Zurück zum Zitat Pfeffer MA et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015;131(1):34-42 Pfeffer MA et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015;131(1):34-42
23.
Zurück zum Zitat Maurer MS et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018;379(11):1007-16 Maurer MS et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018;379(11):1007-16
24.
Zurück zum Zitat MacNee W. Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part One. Am J Respir Crit Care Med. 1994;150(3):833-52 MacNee W. Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part One. Am J Respir Crit Care Med. 1994;150(3):833-52
25.
Zurück zum Zitat Aaron CP et al. Pulmonary vascular volume, impaired left ventricular filling and dyspnea: The MESA Lung Study. PloS one. 2017;12(4):e0176180 Aaron CP et al. Pulmonary vascular volume, impaired left ventricular filling and dyspnea: The MESA Lung Study. PloS one. 2017;12(4):e0176180
26.
Zurück zum Zitat Barr RG et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med. 2010;362(3):217-27 Barr RG et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med. 2010;362(3):217-27
27.
Zurück zum Zitat Kawut SM et al. Cor pulmonale parvus in chronic obstructive pulmonary disease and emphysema: the MESA COPD study. J Am Coll Cardiol. 2014;64(19):2000-9. Kawut SM et al. Cor pulmonale parvus in chronic obstructive pulmonary disease and emphysema: the MESA COPD study. J Am Coll Cardiol. 2014;64(19):2000-9.
28.
Zurück zum Zitat Watz H et al. Decreasing cardiac chamber sizes and associated heart dysfunction in COPD: role of hyperinflation. Chest. 2010;138(1):32-8 Watz H et al. Decreasing cardiac chamber sizes and associated heart dysfunction in COPD: role of hyperinflation. Chest. 2010;138(1):32-8
29.
Zurück zum Zitat Baratto O, Muehsam GE. Heart size in pulmonary emphysema. JAMA. 1968;203(4):293-5 Baratto O, Muehsam GE. Heart size in pulmonary emphysema. JAMA. 1968;203(4):293-5
30.
Zurück zum Zitat Parkinson J, Hoyle C. The Heart in Emphysema. Quart J Med. 1937;6:59-86 Parkinson J, Hoyle C. The Heart in Emphysema. Quart J Med. 1937;6:59-86
31.
Zurück zum Zitat Watz H et al. Emphysema, airflow obstruction, and left ventricular filling. N Engl J Med. 2010;362(17):1638-9 Watz H et al. Emphysema, airflow obstruction, and left ventricular filling. N Engl J Med. 2010;362(17):1638-9
32.
Zurück zum Zitat Jorgensen K et al. Effects of lung volume reduction surgery on left ventricular diastolic filling and dimensions in patients with severe emphysema. Chest. 2003;124(5):1863-70 Jorgensen K et al. Effects of lung volume reduction surgery on left ventricular diastolic filling and dimensions in patients with severe emphysema. Chest. 2003;124(5):1863-70
33.
Zurück zum Zitat Hohlfeld JM et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respir Med. 2018;6(5):368-78 Hohlfeld JM et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respir Med. 2018;6(5):368-78
34.
Zurück zum Zitat Stone IS et al. Lung Deflation and Cardiovascular Structure and Function in Chronic Obstructive Pulmonary Disease. A Randomized Controlled Trial. American journal of respiratory and critical care medicine. 2016;193(7):717-26 Stone IS et al. Lung Deflation and Cardiovascular Structure and Function in Chronic Obstructive Pulmonary Disease. A Randomized Controlled Trial. American journal of respiratory and critical care medicine. 2016;193(7):717-26
35.
Zurück zum Zitat Salpeter SR et al. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004;125(6):2309-21 Salpeter SR et al. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004;125(6):2309-21
36.
Zurück zum Zitat Andreas S et al. Neurohumoral activation as a link to systemic manifestations of chronic lung disease. Chest. 2005;128(5):3618-24 Andreas S et al. Neurohumoral activation as a link to systemic manifestations of chronic lung disease. Chest. 2005;128(5):3618-24
37.
Zurück zum Zitat MacDonald MI et al. Cardiac dysfunction during exacerbations of chronic obstructive pulmonary disease. Lancet Respir Med. 2016;4(2):138-48 MacDonald MI et al. Cardiac dysfunction during exacerbations of chronic obstructive pulmonary disease. Lancet Respir Med. 2016;4(2):138-48
Metadaten
Titel
Zusammenhänge zwischen Lungenerkrankungen und kardialer Dysfunktion
Was der Pneumologe aktuell über das Herz wissen muss
verfasst von
Dr. med. Benjamin Waschki
Publikationsdatum
20.10.2020
Verlag
Springer Medizin
Erschienen in
Pneumo News / Ausgabe 6/2020
Print ISSN: 1865-5467
Elektronische ISSN: 2199-3866
DOI
https://doi.org/10.1007/s15033-020-1917-z

Weitere Artikel der Ausgabe 6/2020

Pneumo News 6/2020 Zur Ausgabe